Our Work
Latham & Watkins Advises on Mirum Pharmaceuticals’ US$600 Million Convertible Senior Notes Offering
May 14, 2026
Multidisciplinary team represents the initial purchasers in the offering by the leading rare disease company.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, announced the pricing of its offering of US$600 million aggregate principal amount of 0.00% convertible senior notes due 2032 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. The issuance and sale of the notes are scheduled to settle on May 15, 2026, subject to customary closing conditions. Mirum also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional US$90 million aggregate principal amount of notes.
Latham & Watkins LLP represents the initial purchasers in the offering with a corporate team led by partners Greg Rodgers, Shayne Kennedy, Arash Aminian Baghai, and Jonathan Sarna, with associates Gregory Van Buiten, Andrew Bentz, Steve Hess, and Austin Urbach. Advice was also provided on tax matters by partner Grace Lee, with associate Jake Meninga; on data privacy matters by partner Heather Deixler, with associate Chad Leiper; on intellectual property matters by counsel Robert Yeh, with associate Patrick Chew; on healthcare regulatory matters by partner Betty Pang; and on FDA regulatory matters by partner Elizabeth Richards and counsel Chad Jennings.